A 52-year-old man with Type 2 diabetes for 8 years presents with acute-onset polyuria, polydipsia, and weight loss over 2 weeks. Laboratory findings show fasting glucose 380 mg/dL, pH 7.28, HCO₃⁻ 12 mEq/L, and serum β-hydroxybutyrate 4.2 mmol/L. Which finding most strongly suggests evolution toward a Type 1-like phenotype rather than typical Type 2 decompensation?

Explanation

## Type 1-Like Phenotype in Type 2 Diabetes (LADA and β-Cell Failure) ### Clinical Scenario: Latent Autoimmune Diabetes in Adults (LADA) **Key Point:** LADA is a slowly progressive autoimmune form of diabetes that mimics Type 2 initially but evolves toward absolute insulin deficiency. It accounts for 5–15% of "Type 2" diagnoses in adults and is distinguished from true Type 2 by the presence of anti-islet antibodies and rapid loss of β-cell function. ### Discriminating Feature: C-Peptide + Autoimmune Markers | Feature | Typical Type 2 Decompensation | LADA / Type 1-Like Evolution | |---------|-------------------------------|-----------------------------| | **C-peptide** | Detectable (>0.3 ng/mL) | Undetectable (<0.3 ng/mL) | | **Anti-islet antibodies** | Absent | Present (anti-GAD, anti-IA2, anti-ZnT8) | | **Insulin requirement** | Delayed (years to decades) | Rapid (months to 1–2 years) | | **Ketosis-prone** | Rare without infection/stress | Common, even without severe stress | | **Response to oral agents** | Initial good response | Rapid loss of efficacy | **High-Yield:** The combination of **undetectable C-peptide + positive anti-islet antibodies** in a patient initially labeled "Type 2" is diagnostic of LADA or Type 1-like evolution. This indicates autoimmune β-cell destruction, not insulin resistance. ### Why This Patient Likely Has LADA 1. **Acute decompensation after 8 years** of apparent Type 2 stability suggests a sudden shift in pathophysiology. 2. **Metabolic acidosis with high ketone bodies** in a non-obese, weight-losing patient points to absolute insulin deficiency (Type 1 mechanism) rather than relative deficiency (Type 2 mechanism). 3. **Low C-peptide + anti-GAD antibodies** confirm autoimmune destruction, not insulin resistance. **Clinical Pearl:** LADA is often misdiagnosed as Type 2 in middle-aged patients because it presents gradually. However, the presence of anti-islet antibodies reveals the true autoimmune nature. These patients eventually require insulin, unlike most Type 2 patients. ### Why Other Options Are Not Discriminating **Option B (Acute metabolic acidosis with elevated ketones):** While suggestive of absolute insulin deficiency, DKA can occur in Type 2 under acute stress (infection, MI, surgery) or in certain populations. It is not specific for autoimmune disease. **Option C (Severe hyperglycemia with osmotic symptoms):** Both Type 1 and Type 2 can present with severe hyperglycemia. This reflects the degree of glycemic control loss, not the underlying pathophysiology. **Option D (Absence of obesity and weight loss):** While Type 1 patients are typically lean, some Type 2 patients are also non-obese (especially in Asian populations). Weight loss occurs in both conditions when insulin deficiency is severe. This is not a discriminating feature.